Different types of renal dysfunction in patients with acute myocardial infarction treated with percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 20, Issue 2, 2007, Pages 143-152

  Kowalczyk, Jacek ^a   Lenarczyk, Radoslaw ^a   Kowalski, Oskar ^a   Sredniawa, Beata ^a   Musialik Lydka, Agata ^a   Gasior, Mariusz ^a   Polonski, Lech ^a   Zembala, Marian ^a   Gumprecht, Janusz ^a   Kalarus, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGISTER; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL TIME;

ACUTE DISEASE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33947425554     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00253.x     Document Type: Article

References (47)

1. Gerstein HC, Bosch, J, Pogue, J, et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996;19:1225-1228.
2. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
3. Gerstein HC, Pogue, J, Mann JF, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis. Diabetologia 2005;48:1749-1755.
4. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002;18(Suppl.)3:S82-S85.
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
6. Mann JF, Gerstein HC, Yi QL, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003;42:936-942.
7. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: Results of the HOPE randomized study. J Am Soc Nephrol 2003;14:641-647.
8. Mahon NG, Blackstone EH, Francis GS, et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002;40:1106-1113.
9. Naidu SS, Selzer, F, Jacobs, A, et al. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol 2003;92:1160-1164.
10. Gurm HS, Lincoff AM, Kleiman NS, et al. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol 2004;94:30-34.
11. Al Suwaidi, J, Reddan DN, Williams, K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974-980.
12. Masoudi FA, Plomondon ME, Magid DJ, et al. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 2004;147:623-629.
13. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-2775.
14. Deedwania PC. Diabetes and hypertension, the deadly duet: Importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin 2005;23:139-152.
15. Guzder RN, Gatling, W, Mullee MA, et al. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: Results from a United Kingdom study. Diabet Med 2005;22:554-562.
16. Hansson, L, Zanchetti, A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-1762.
17. Hansson, L. The Hypertension Optimal Treatment Study and the importance of lowering blood pressure. J Hypertens Suppl 1999;17:S9-S13.
18. Nilsson, P. What is the optimal blood pressure in patients with diabetes mellitus? Am J Cardiovasc Drugs 2001;1:173-177.
19. Zanchetti, A, Hansson, L, Clement, D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT Study with different risk profiles: Does a J-shaped curve exist in smokers? J Hypertens 2003;21:797-804.
20. Zanchetti, A, Hansson, L, Dahlof, B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001;19:1149-1159.
21. Walsh CR, O'Donnell CJ, Camargo CA Jr, et al. Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am Heart J 2002;144:1003-1011.
22. Shlipak MG, Heidenreich PA, Noguchi, H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-562.
23. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 2002;137:563-570.
24. West AJ, Dixon SR, Kahn JK, et al. Effectiveness of primary angioplasty for acute myocardial infarction in patients on dialysis. Am J Cardiol 2004;93:468-470.
25. Yamaguchi, J, Kasanuki, H, Ishii, Y, et al. Prognostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who underwent successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] Registry). Am J Cardiol 2004;93:1526-1528.
26. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
27. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003;41:725-728.
28. Han JH, Chandra, A, Mulgund, J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 2006;119:248-254.
29. Brosius FC 3rd, Hostetter TH, Kelepouris, E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation 2006;114:1083-1087.
30. Levey AS, Coresh, J, Balk, E, et al., National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. [Published correction in Ann Intern Med 2003;139:605. Published comments in Ann Intern Med 2003;139:I36, Ann Intern Med 2004;140:933-934; author reply 934-935]. Ann Intern Med 2003;139:137-147.
31. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl.1):S1-S237.
32. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
33. McCullough PA, Adam A, Becker CR, et al., CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98(6A):5K-13K.
34. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. TheTask Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
35. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840.
36. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-1900.
37. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2000;102:1193-1209.
38. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
39. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-305.
40. Klein LW, Shaw RE, Krone RJ, et al. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol 2005;96:35-41.
41. Goldenberg I, Matetzky S, et al. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ 2005;172:1461-1471.
42. McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002;162:2464-2468.
43. McCullough PA, et al. Cardiorenal risk: An important clinical intersection. Rev Cardiovasc Med 2002;3:71-76.
44. Tumlin J, Stacul F, Adam A, et al. CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98(6A):14K-20K.
45. Fernandez JS, Sadaniantz BT, Sadaniantz A, et al. Review of antithrombotic agents used for acute coronary syndromes in renal patients. Am J Kidney Dis 2003;42:446-455.
46. Davidson C, Stacul F, McCullough PA, et al., CIN Consensus Working Panel. Contrast medium use. Am J Cardiol 2006;98(6A):42K-58K.
47. McCullough PA, Adam A, Becker CR, et al., CIN Consensus Working Panel. Risk Prediction of contrast-induced nephropathy. Am J Cardiol 2006;98:27K-36K.